Drug Profile
Research programme: anti-CD155 antibodies - Biotecnol
Latest Information Update: 14 Jun 2012
Price :
$50
*
At a glance
- Originator Biotecnol SA
- Class Antibodies
- Mechanism of Action CD antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Nov 2007 The anti-CD155 antibody programme is available for licensing worldwide (http://www.biotecnol.com/default.aspx?classification=00003201:00000001)
- 15 Nov 2007 Preclinical trials in Solid tumours in Portugal (Parenteral)